Dr Joaquin Mateo, (Institute of Cancer Research, London, UK) speaks to ecancertv at ASCO GU 2015 following results from the Phase II trial using abiraterone and cabazitaxel combination in metastatic castration-resistant prostate cancer where it's found to be well tolerated and demonstrated antitumor activity in the post-docetaxel, post-abiraterone setting.

свернуть